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Disease severity in patientswith pulmonary tuberculosis is associatedwithmycobacterial sputum load. To ascertainwhether reduced
sputumproduction during treatment is a useful clinical sign of improvement, we analyzed themycobacterial loads of 5,552 sputum
samples collected from439newly diagnosed sputum smear-positive tuberculosis patientswhoparticipated in six 14-day studies of
antituberculosis treatment. Sputumvolumeswere categorized as low (<6ml),medium (6 to 10ml), or large (>10ml), andmycobacte-
rial loadwasmeasured by the time to positivity in liquid culture and theCFU counts on solid culture. The association of sputumvol-
umewithmycobacterial loadwas estimatedwithmultiple linear regressionmodels adjusted for repeatedmeasures. The predictor vari-
ableswere sputumvolume category, treatment day, specific study , and the interaction of sputumvolume category and treatment day.
Mycobacterial loadwas significantly associated onlywith the day on treatment and sputumvolume,which tended to decreasewith
ongoing treatment.With the volumeheld constant, each day on treatment decreased the logCFUby 0.082 (P< 0.001) and increased
the time to positivity (TTP) by 1.04 h (P< 0.001). From low tomediumand frommedium to large sputumvolumes, the logCFU/ml
increased by 0.265 (P< 0.003) and 0.490 (P< 0.001), respectively, and theTTPdecreased by 1.17 h (P< 0.001) and 1.30 h (P< 0.001),
respectively, for a given day of treatment. The variability of the sputum loadmeasurements increasedwith the day of treatment and
lower sputumvolumes. The significant association of sputumvolume andmycobacterial load validates decreasing sputumproduction
as a clinical sign of improvement during early antituberculosis treatment.
Tuberculosis (TB) remains a major cause of morbidity andmortality worldwide. In 2012, theWorld Health Organization
(WHO) estimated that 8.5 million new TB cases and 1.3 million
TB deaths occurred globally (1). In 2008, the incidence of TB in
South Africa was 960 cases per 100,000 people, with an annual
increase of 6.4% from 1998 to 2008 (2). TB is most commonly
diagnosed by the identification of Mycobacterium tuberculosis in
expectorated spot sputum specimens, either by sputum smearmi-
croscopy or by the identification of mycobacterial antigens with
PCR (3). The viable sputum mycobacterial load can be measured
by counting CFU on agar plates or by the time to positivity (TTP)
in culture with liquid medium (4–6). Greater initial spot sputum
mycobacterial burden has been linked tomore extensive radiolog-
ical lung involvement, worse treatment outcomes, and a higher
risk of relapse (7–9), and more recently, greater sputum volume
has been linked to worse treatment outcomes in HIV-infected TB
patients (10).
The decrease in the sputum mycobacterial burden in pooled
16-h sputum samples collected overnight is an established mea-
sure of early antituberculosis drug effects over the first 2 weeks of
treatment (11), but few studies have assessed the association of
sputum volumes with measurements of mycobacterial load. In a
trial reported in 1950, before effective treatments became avail-
able, it was documented that hospitalized patients treated with a
placebo had stable sputum volumes and percentages of positive
smears over 14 weeks, whereas para-aminosalicylic acid-treated
patients experienced reductions in both (12). Yoon, Lee, and Yim
(13) found that purulent or blood-tinged sputum, as well as a
larger volume of early morning and spot sputum samples pre-
dicted smear positivity.
TB patients frequently report a prompt reduction in produc-
tive coughs upon the initiation of treatment. This is commonly
accepted as a clinical sign of improvement. The purpose of this
study was to substantiate this association by investigating whether
decreased sputum volume is associated with a reduced sputum
mycobacterial load during early antituberculosis treatment.
MATERIALS AND METHODS
Studypopulation and specimens.Westudied the sputumsamples from6
consecutive 14-day early bactericidal activity (EBA) studies conducted
between 2008 and 2012. The locations, procedures, and relevant partici-
pation criteria were identical for all the studies. The subjects were re-
cruited from outpatient clinics in Cape Town, South Africa, and were
enrolled if they were aged 18 to 65 years, had1 smear-positive sputum
on auramine microscopy (International Union Against Tuberculosis and
Lung Disease [IUATLD]/WHO scale) (14), and were without major un-
derlying medical conditions. Spontaneously expectorated sputum sam-
ples were collected over a period of 16 h overnight, refrigerated, and sent
to a single laboratory in Cape Town under controlled conditions.
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Laboratory methods. During the entire study period, the laboratory
supplied the clinical sites with identical, transparent, and wide-mouthed
collection containers of 125 ml in volume and with a screw top (Scientific
Group, Vorna Valley, South Africa). Upon submission to the laboratory,
two technologists trained on sample reception were in charge of estimat-
ing the sputum volumes by comparing the containers to reference con-
tainers filled with standard volumes of water. Sputum volume was cate-
gorized arbitrarily as 6 ml, 6 to 10 ml, or 10 ml. Discrepancies were
resolved by consensus between the two technologists. All studies em-
ployed the same standardized laboratory methodology for processing.
The sputum samples were homogenized using magnetic stirring and the
addition of 0.1% dithiothreitol (Sputasol; Oxoid, Cambridge, United
Kingdom) for digestion. All samples were assessed for mycobacterial load
by both CFU count and TTP.
For CFU quantification, 10-fold serial dilutions were inoculated onto
two halves of two 7H11 agar biplates. The plates were then incubated at
37°C for a period of 3 weeks, and the CFUwere counted using the dilution
with counts between 20 and 200. After calculating an average of the du-
plicate CFU counts and correcting for the dilution factor, the results were
reported as the CFU per ml of sputum.
For TTP determination, digested sputum was decontaminated for 15
min at room temperature by using sodium hydroxide at a final concen-
tration of 1% (MycoPrep; Becton Dickinson, Sparks, MD). The specimen
was then neutralized using phosphate-buffered saline (pH 6.8) (Becton
Dickinson) and concentrated through centrifugation (15 min at 3,000
g and 4°C). The supernatantwas then decanted and the pellet resuspended
to a volume of 2 ml using phosphate-buffered saline. The resuspended
pellet was then used to inoculate duplicate mycobacterial growth indica-
tor tubes (MGITs) (BectonDickinson) that were enrichedwith oleic acid-
albumin-dextrose-catalase [OADC]; Becton Dickinson) and polymyxin
B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin (PANTA)
(Becton Dickinson). The MGITs were then incubated at 37°C in the Bac-
tec MGIT 960 instrument (Becton Dickinson), which monitors the cul-
tures and automatically records the TTP once the culture is flagged as
positive.
Data collection. The data obtained included individual patient, spe-
cific study, sputum volume, treatment day, TTP, and CFU. Negative cul-
tures were excluded for the CFU counts. For TTP determination, negative
cultures were censored at 42 days (the maximum length of culture incu-
bation), and this value was used for analysis.
Statistical methods. The data from all six studies were combined for
statistical analysis. Due to the similar inclusion and exclusion criteria,
identical source population, and the single laboratory that processed
all samples with identical methods, we considered the population not
to be clinically heterogeneous. Because the studies were conducted in
sequence and, generally, groups within a study were given variations of
the same treatment, we adjusted for study but not for individual treat-
ment groups. Neither CFU nor TTP were normally distributed and
were both log10 transformed. The means, standard deviations, and
coefficients of variation of the log TTP and log CFU were reported by
volume category. Simple linear regression analysis was used to deter-
mine the effect of time on log TTP and log CFU within the different
volume categories.
Twomultiple linear regressionmodels were used to estimate the asso-
ciation between sputum volume and the log TTP and log CFU. In order to
take into account the correlation of observations within a single partici-
pant (cluster), we adjusted the models for the effect of repeated measures
per patient by using robust standard errors based on patient number as
the cluster variable. The predictor variables included in the initial models
were the same for both log TTP and log CFU. They included volume, time
on treatment (in days), study code (A to F), and the interaction between
volume and time. The final adjusted models were obtained using a back-
ward stepwise approach, and variables with a P value of 0.1 were re-
tained. All statistical analyses were performed using the Stata software
(version 12).
Ethical approval. The protocol for this study was reviewed and ap-
proved by the ethics committee of the University of Stellenbosch, Stellen-
bosch, South Africa (reference S12/11/310). The study was carried out
between June and December 2013.
TABLE 1 Specimens and mycobacterial load measurements
Study
No. of
patients
No. of
samples
Mean no. (SD) of
samples per patient
log CFU/ml sputum log TTPa
Valid no. (%) of
specimens Mean SD
Valid no. (%) of
specimens Mean SD
A 68 745 11 (0.3) 646 (86.7) 4.5 1.8 716 (96.1) 2.2 0.2
B 85 1,310 15 (2.2) 1,209 (92.3) 5.1 1.5 1,283 (97.9) 2.2 0.2
C 69 752 11 (0.8) 714 (94.9) 5.3 1.3 735 (97.7) 2.1 0.1
D 59 470 8 (0.2) 426 (90.6) 5.1 1.4 456 (97.0) 2.2 0.2
E 68 854 12 (1.7) 825 (96.6) 5.8 1.1 771 (90.3) 2.1 0.2
F 90 1,421 15 (1.5) 1,247 (87.8) 5.3 1.5 1,383 (97.3) 2.1 0.2
Total 439 5,552 13 (3.1) 5,067 (91.3) 5.2 1.5 5,344 (96.3) 2.2 0.2
a TTP, time to culture positivity.
TABLE 2 Sputum volume and mycobacterial load measurements
Vol (ml)
No. (%) of samples ata: Log CFU/ml sputum Log TTP (h)b TTP (h)
Total Day 0 Day 6 Day 14 Mean SD CV Mean SD CV Median IQRc
6 655 (12.2) 75 (8.6) 56 (13.0) 66 (15.7) 4.7 1.7 0.359 2.2 0.2 0.094 166 127–232
6–10 2,325 (43.3) 363 (41.8) 196 (45.5) 190 (45.1) 5.1 1.5 0.301 2.2 0.2 0.089 140 105–197
10 2,392 (44.5) 431 (49.6) 179 (41.5) 165 (39.2) 5.4 1.4 0.253 2.1 0.2 0.077 123 100–161
Total 5,372 (100) 869 (100) 431 (100) 421 (100) 5.0 1.5 0.301 2.2 0.2 0.080 134 104–186
a Days 0 (baseline), 6, and 14 are given as examples.
b TTP, time to culture positivity; CV, coefficient of variation.
c IQR, interquartile range.
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RESULTS
Studies, participants, and specimens. In 6 EBA studies (59 to 90
participants per study) and 30 treatment groups (8 to 25 partici-
pants per group), the 439 participants produced a total of 5,552
sputum samples (4 to 16 per participant, and 470 to 1,421 per
study). Table 1 shows the distribution, means, and standard devi-
ations of 5,067 valid CFU and 5,344 valid TTPmeasurements.We
excluded 8.7% and 3.7% of the CFU and TTP results, respectively,
for contamination (4.6% and 1.7%, respectively) and negative or
missing results (4.1% and 2.0%, respectively).
Sputum volumes. The specimen volume categories, with the
distribution over time, mean values, standard deviations, and co-
efficients of variation are shown in Table 2. The sputum volumes
tended to decrease over time, and the variabilities of both mea-
FIG 1 Box plots of log CFU (top) and log TTP (bottom) for treatment days 0 to 14. The volume categories are6 ml (top), 6 to 10 ml (middle), and10 ml
(bottom). In each volume category, there was a statistically significant decrease in log CFU and increase in log TTP over time (both P 0.001). BL, baseline.
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surements increased as the sample volumes decreased. In all vol-
ume categories, considerably less variability was observed with
TTP, which had a 3- to 4-fold smaller coefficient of variation than
that for CFU. A statistically significant decrease in log CFU and an
increase in log TTP (Fig. 1A and B) were observed in all volume
categories over time (P 0.001).
Statisticalmodeling.Among all the outcomes tested, only vol-
ume and days on treatment showed significant associations with
log CFU and log TTP (Tables 3 and 4). All outcomes were highly
significant. Themean log CFU decreased, on average, by 0.082 log
CFU for each day on treatment, with volume being held constant
(P 0.001). From6 ml to between 6 and 10 ml, and 6 to 10 ml
to10ml of sputum volume, the log CFU increased by 0.265 and
0.490, respectively. Correspondingly, the non-log-transformed
TTP increased by 1.04 h per day on treatment, with the volume
held constant (P  0.001). As the specimen volumes increased
from6 ml to between 6 and 10 ml, and from 6 to 10 ml to10
ml, the TTP decreased by 1.172 h and 1.297 h, respectively.
DISCUSSION
We found that the volume of sputum expectorated overnight by
pulmonary TB patients was positively associated with the myco-
bacterial sputum load. The sputum volumes became smaller over
the first 14 days of treatment and exhibited increased TTP and
decreased CFU. This validates the clinical observation that pa-
tients reporting diminishing sputum production are responding
to treatment, as evidenced by a decrease in themycobacterial spu-
tum load.
The decrease in mycobacterial load depicted in the prolon-
gation of TTP and decreased CFU is an expected response to
treatment, as is the reduction in productive cough. This study
exemplifies a well-known dilemma in clinical trials of antitu-
berculosis treatments. Sputum, as the substrate of the main
endpoint measurement of trials, becomes smaller in volume
over time, and the variation in its mycobacterial load measure-
ments increases. This makes significant differences between
treatments harder to detect with ongoing treatment duration,
particularly when measured with CFU, for which we found a
much larger variation than that for TTP. It has been observed
that a longer daily collection period increases sputum volume
and leads to an increase in the precision of CFU (15), and that
EBAs obtained from pooled sputum specimens that usually
have higher volumes (10 ml) have a lower standard error
than estimates obtained from spot sputum samples with vol-
umes of 5 ml (5).
The strength of this study is the large number of aggregated
observations from large EBA studies, which increases the preci-
sion due to the large sample size. The studies were combined on
the basis that all participants were from the same source popula-
tion and that each of the studies have comparable eligibility crite-
ria. Furthermore, all samples were analyzed by the same labora-
tory using standardized protocols. However, the studies differed
in their treatment groups. We were blinded as to which treatment
arm receivedwhich type and dosage of treatment, but the diversity
in treatments and the small sample size in each treatment arm
might be limitations of this study. Also, only aminority of patients
were on treatments as efficacious as that of the currently used
combination therapy. Standard treatment (body weight-adjusted
isoniazid, rifampin, pyrazinamide, and ethambutol) increases the
TTP by approximately 13 h per day and decreases the CFU by
0.177 log CFU over the first 14 days of treatment (16). The overall
mean change inmycobacterial loadwas only about half that in our
analysis (46% for CFU and 52% for non-log-transformed TTP).
Our data might thus still underestimate the drop in sputum vol-
umes and the increases in load measurement variation that might
be observed if fully effective treatments are studied.
In conclusion, reduced sputum volume predicts a decrease in
mycobacterial sputum load in patients with pulmonary TB. Cli-
nicians can interpret a reduced productive cough in the first 14
days of therapy as a valid clinical sign of effective treatment.
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